SARTORIUS STEDIM BIOTECH (56S1.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:56S1 - FR0013154002 - Common Stock
210.1 EUR
+0.2 (+0.1%)
Taking everything into account, 56S1 scores 4 out of 10 in our fundamental rating. 56S1 was compared to 20 industry peers in the Life Sciences Tools & Services industry. While 56S1 is still in line with the averages on profitability rating, there are concerns on its financial health. 56S1 is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year 56S1 was profitable.
- 56S1 had a positive operating cash flow in the past year.
- 56S1 had positive earnings in each of the past 5 years.
- In the past 5 years 56S1 always reported a positive cash flow from operatings.
1.2 Ratios
- 56S1 has a worse Return On Assets (3.36%) than 65.00% of its industry peers.
- 56S1 has a worse Return On Equity (6.55%) than 60.00% of its industry peers.
- 56S1 has a Return On Invested Capital of 5.94%. This is comparable to the rest of the industry: 56S1 outperforms 50.00% of its industry peers.
- 56S1 had an Average Return On Invested Capital over the past 3 years of 10.41%. This is in line with the industry average of 9.00%.
- The last Return On Invested Capital (5.94%) for 56S1 is well below the 3 year average (10.41%), which needs to be investigated, but indicates that 56S1 had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.36% | ||
| ROE | 6.55% | ||
| ROIC | 5.94% |
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
1.3 Margins
- 56S1 has a Profit Margin of 8.98%. This is comparable to the rest of the industry: 56S1 outperforms 55.00% of its industry peers.
- In the last couple of years the Profit Margin of 56S1 has declined.
- 56S1 has a Operating Margin (16.63%) which is in line with its industry peers.
- In the last couple of years the Operating Margin of 56S1 has declined.
- The Gross Margin of 56S1 (45.64%) is better than 65.00% of its industry peers.
- In the last couple of years the Gross Margin of 56S1 has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.63% | ||
| PM (TTM) | 8.98% | ||
| GM | 45.64% |
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so 56S1 is still creating some value.
- The number of shares outstanding for 56S1 has been increased compared to 1 year ago.
- The number of shares outstanding for 56S1 has been increased compared to 5 years ago.
- The debt/assets ratio for 56S1 has been reduced compared to a year ago.
2.2 Solvency
- 56S1 has an Altman-Z score of 4.50. This indicates that 56S1 is financially healthy and has little risk of bankruptcy at the moment.
- 56S1's Altman-Z score of 4.50 is fine compared to the rest of the industry. 56S1 outperforms 75.00% of its industry peers.
- 56S1 has a debt to FCF ratio of 6.84. This is a slightly negative value and a sign of low solvency as 56S1 would need 6.84 years to pay back of all of its debts.
- 56S1 has a Debt to FCF ratio of 6.84. This is in the lower half of the industry: 56S1 underperforms 60.00% of its industry peers.
- A Debt/Equity ratio of 0.50 indicates that 56S1 is not too dependend on debt financing.
- With a Debt to Equity ratio value of 0.50, 56S1 perfoms like the industry average, outperforming 55.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 6.84 | ||
| Altman-Z | 4.5 |
ROIC/WACC0.64
WACC9.35%
2.3 Liquidity
- A Current Ratio of 1.05 indicates that 56S1 should not have too much problems paying its short term obligations.
- Looking at the Current ratio, with a value of 1.05, 56S1 is doing worse than 70.00% of the companies in the same industry.
- A Quick Ratio of 0.50 indicates that 56S1 may have some problems paying its short term obligations.
- 56S1 has a Quick ratio of 0.50. This is amonst the worse of the industry: 56S1 underperforms 80.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.05 | ||
| Quick Ratio | 0.5 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 35.11% over the past year.
- Measured over the past 5 years, 56S1 shows a small growth in Earnings Per Share. The EPS has been growing by 4.19% on average per year.
- 56S1 shows a small growth in Revenue. In the last year, the Revenue has grown by 7.72%.
- The Revenue has been growing by 14.05% on average over the past years. This is quite good.
EPS 1Y (TTM)35.11%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%23.68%
Revenue 1Y (TTM)7.72%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%7.67%
3.2 Future
- 56S1 is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.17% yearly.
- The Revenue is expected to grow by 9.86% on average over the next years. This is quite good.
EPS Next Y29.39%
EPS Next 2Y23.86%
EPS Next 3Y23.06%
EPS Next 5Y21.17%
Revenue Next Year7.45%
Revenue Next 2Y8.04%
Revenue Next 3Y9.07%
Revenue Next 5Y9.86%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 48.75 indicates a quite expensive valuation of 56S1.
- Based on the Price/Earnings ratio, 56S1 is valued more expensive than 80.00% of the companies in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 27.38, 56S1 is valued quite expensively.
- A Price/Forward Earnings ratio of 39.13 indicates a quite expensive valuation of 56S1.
- Based on the Price/Forward Earnings ratio, 56S1 is valued expensively inside the industry as 80.00% of the companies are valued cheaper.
- 56S1 is valuated expensively when we compare the Price/Forward Earnings ratio to 24.29, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 48.75 | ||
| Fwd PE | 39.13 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, 56S1 is valued expensively inside the industry as 85.00% of the companies are valued cheaper.
- 65.00% of the companies in the same industry are cheaper than 56S1, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 54.59 | ||
| EV/EBITDA | 28.11 |
4.3 Compensation for Growth
- The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- 56S1's earnings are expected to grow with 23.06% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.66
PEG (5Y)11.62
EPS Next 2Y23.86%
EPS Next 3Y23.06%
5. Dividend
5.1 Amount
- With a yearly dividend of 0.32%, 56S1 is not a good candidate for dividend investing.
- Compared to an average industry Dividend Yield of 0.54, 56S1 is paying slightly less dividend.
- Compared to an average S&P500 Dividend Yield of 1.85, 56S1's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.32% |
5.2 History
- The dividend of 56S1 has a limited annual growth rate of 4.44%.
Dividend Growth(5Y)4.44%
Div Incr Years0
Div Non Decr Years1
5.3 Sustainability
- 25.37% of the earnings are spent on dividend by 56S1. This is a low number and sustainable payout ratio.
- The dividend of 56S1 is growing, but earnings are growing more, so the dividend growth is sustainable.
DP25.37%
EPS Next 2Y23.86%
EPS Next 3Y23.06%
FRA:56S1 (1/15/2026, 7:00:00 PM)
210.1
+0.2 (+0.1%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)10-16 2025-10-16/bmo
Earnings (Next)02-03 2026-02-03/amc
Inst Owners11.88%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap20.45B
Revenue(TTM)2.95B
Net Income(TTM)264.50M
Analysts81.11
Price Target247.31 (17.71%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.32% |
Yearly Dividend0.71
Dividend Growth(5Y)4.44%
DP25.37%
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.99%
Min EPS beat(2)-2.24%
Max EPS beat(2)10.22%
EPS beat(4)3
Avg EPS beat(4)9.45%
Min EPS beat(4)-2.24%
Max EPS beat(4)22.18%
EPS beat(8)3
Avg EPS beat(8)-1.58%
EPS beat(12)3
Avg EPS beat(12)-11.08%
EPS beat(16)4
Avg EPS beat(16)-13.1%
Revenue beat(2)1
Avg Revenue beat(2)-1.82%
Min Revenue beat(2)-3.94%
Max Revenue beat(2)0.3%
Revenue beat(4)3
Avg Revenue beat(4)0.7%
Min Revenue beat(4)-3.94%
Max Revenue beat(4)3.52%
Revenue beat(8)5
Avg Revenue beat(8)-0.23%
Revenue beat(12)5
Avg Revenue beat(12)-1.54%
Revenue beat(16)7
Avg Revenue beat(16)-0.72%
PT rev (1m)2.75%
PT rev (3m)3.28%
EPS NQ rev (1m)0%
EPS NQ rev (3m)11.67%
EPS NY rev (1m)-0.01%
EPS NY rev (3m)1.39%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.67%
Revenue NY rev (1m)-1.45%
Revenue NY rev (3m)-1.45%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 48.75 | ||
| Fwd PE | 39.13 | ||
| P/S | 6.94 | ||
| P/FCF | 54.59 | ||
| P/OCF | 27.99 | ||
| P/B | 5.07 | ||
| P/tB | N/A | ||
| EV/EBITDA | 28.11 |
EPS(TTM)4.31
EY2.05%
EPS(NY)5.37
Fwd EY2.56%
FCF(TTM)3.85
FCFY1.83%
OCF(TTM)7.51
OCFY3.57%
SpS30.27
BVpS41.47
TBVpS-4.02
PEG (NY)1.66
PEG (5Y)11.62
Graham Number63.42
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.36% | ||
| ROE | 6.55% | ||
| ROCE | 7.46% | ||
| ROIC | 5.94% | ||
| ROICexc | 6.26% | ||
| ROICexgc | 21.64% | ||
| OM | 16.63% | ||
| PM (TTM) | 8.98% | ||
| GM | 45.64% | ||
| FCFM | 12.71% |
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
ROICexc(3y)10.84%
ROICexc(5y)15.37%
ROICexgc(3y)26.31%
ROICexgc(5y)36.49%
ROCE(3y)13.07%
ROCE(5y)18.3%
ROICexgc growth 3Y-36.77%
ROICexgc growth 5Y-16.49%
ROICexc growth 3Y-43.34%
ROICexc growth 5Y-25.09%
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
F-Score8
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 6.84 | ||
| Debt/EBITDA | 2.5 | ||
| Cap/Depr | 112.98% | ||
| Cap/Sales | 12.09% | ||
| Interest Coverage | 3.09 | ||
| Cash Conversion | 90.75% | ||
| Profit Quality | 141.63% | ||
| Current Ratio | 1.05 | ||
| Quick Ratio | 0.5 | ||
| Altman-Z | 4.5 |
F-Score8
WACC9.35%
ROIC/WACC0.64
Cap/Depr(3y)182.98%
Cap/Depr(5y)186.68%
Cap/Sales(3y)13.87%
Cap/Sales(5y)12.23%
Profit Quality(3y)126.76%
Profit Quality(5y)109.63%
High Growth Momentum
Growth
EPS 1Y (TTM)35.11%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%23.68%
EPS Next Y29.39%
EPS Next 2Y23.86%
EPS Next 3Y23.06%
EPS Next 5Y21.17%
Revenue 1Y (TTM)7.72%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%7.67%
Revenue Next Year7.45%
Revenue Next 2Y8.04%
Revenue Next 3Y9.07%
Revenue Next 5Y9.86%
EBIT growth 1Y25.48%
EBIT growth 3Y-23.35%
EBIT growth 5Y2.67%
EBIT Next Year93.64%
EBIT Next 3Y36.06%
EBIT Next 5Y27.25%
FCF growth 1Y219.35%
FCF growth 3Y7.94%
FCF growth 5Y22.24%
OCF growth 1Y15.98%
OCF growth 3Y5.11%
OCF growth 5Y21.32%
SARTORIUS STEDIM BIOTECH / 56S1.DE FAQ
What is the ChartMill fundamental rating of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
ChartMill assigns a fundamental rating of 4 / 10 to 56S1.DE.
Can you provide the valuation status for SARTORIUS STEDIM BIOTECH?
ChartMill assigns a valuation rating of 1 / 10 to SARTORIUS STEDIM BIOTECH (56S1.DE). This can be considered as Overvalued.
How profitable is SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
SARTORIUS STEDIM BIOTECH (56S1.DE) has a profitability rating of 5 / 10.
Can you provide the PE and PB ratios for 56S1 stock?
The Price/Earnings (PE) ratio for SARTORIUS STEDIM BIOTECH (56S1.DE) is 48.75 and the Price/Book (PB) ratio is 5.07.
What is the earnings growth outlook for SARTORIUS STEDIM BIOTECH?
The Earnings per Share (EPS) of SARTORIUS STEDIM BIOTECH (56S1.DE) is expected to grow by 29.39% in the next year.